WB 001
Alternative Names: WB-001Latest Information Update: 01 Aug 2025
At a glance
- Originator Hangzhou Weben Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myc modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 23 Jul 2025 Preclinical trials in Gastric cancer in China (PO), prior to July 2025 (Hangzhou Weben Pharma pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Lung cancer in China (PO), prior to July 2025 (Hangzhou Weben Pharma pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Pancreatic cancer in China (PO), prior to July 2025 (Hangzhou Weben Pharma pipeline, July 2025)